Tayyab Asma, Asif Alvina, Qazi Shaista, Wahid Sughra, Zafar Anam, Halim Michael, Hussain Irshad, Mumtaz Hassan
Senior Registrar Paediatrics, Islamabad Medical and Dental College, Pakistan.
Head of Department Paediatrics, KRL Hospital Islamabad, Pakistan.
Ann Med Surg (Lond). 2022 Nov 8;84:104799. doi: 10.1016/j.amsu.2022.104799. eCollection 2022 Dec.
Asthma is one of the most common chronic diseases in children and worldwide its prevalence has increased dramatically in the last three decades. We aimed to compare single dose oral dexamethasone versus multiple doses of oral prednisolone in children with acute exacerbation of asthma in terms of post treatment requirement of systemic steroids.
This Randomized control trial has been conducted in the Department of paediatrics, KRL Hospital, Islamabad from Dec 2018 to June 2019.312 patients between the age of 2-12 years patients were randomized into Group A receiving a STAT single dose of oral dexamethasone 0.3 mg/kg and Group B receiving prednisolone 1 mg/kg/day followed by two doses on Day 2 and 3. further dose of systemic steroids were ascertained through PRAM score.
In this study mean age in Group A was 8 years with SD ± 5.68 while mean age in Group B was 7 years with SD ± 6.12. In Group A 58% patients were male and 42% patients were female. Whereas in Group B 59% patients were male and 41% patients were female. In Group A 12% patients had further requirement of systemic steroids while in Group B 18% patients had further requirement of systemic steroids while 82% patients didn't had further requirement of systemic steroids.
Our study concludes that post treatment requirement of systemic steroids is less in single dose oral dexamethasone as compare to multiple doses of oral prednisolone in children with acute exacerbation of asthma.
哮喘是儿童中最常见的慢性疾病之一,在全球范围内,其患病率在过去三十年中急剧上升。我们旨在比较单剂量口服地塞米松与多剂量口服泼尼松龙对哮喘急性加重患儿全身用类固醇激素治疗后的需求情况。
本随机对照试验于2018年12月至2019年6月在伊斯兰堡KRL医院儿科进行。312例年龄在2至12岁的患者被随机分为A组,接受单次口服地塞米松0.3mg/kg,B组接受泼尼松龙1mg/kg/天,随后在第2天和第3天各服用两剂。通过PRAM评分确定全身用类固醇激素的进一步剂量。
本研究中,A组的平均年龄为8岁,标准差±5.68,而B组的平均年龄为7岁,标准差±6.12。A组中58%的患者为男性,42%为女性。而B组中59%的患者为男性,41%为女性。A组中12%的患者需要进一步使用全身用类固醇激素,而B组中18%的患者需要进一步使用全身用类固醇激素,82%的患者不需要进一步使用全身用类固醇激素。
我们的研究得出结论,对于哮喘急性加重的儿童,单剂量口服地塞米松治疗后全身用类固醇激素的需求比多剂量口服泼尼松龙少。